Pardes Biosciences (Pardes Biosciences) Debt-to-Asset : 0.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Pardes Biosciences Debt-to-Asset?

Pardes Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Pardes Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Pardes Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $157.31 Mil. Pardes Biosciences's debt to asset for the quarter that ended in Jun. 2023 was 0.00.

Pardes Biosciences Debt-to-Asset Historical Data

The historical data trend for Pardes Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pardes Biosciences Debt-to-Asset Chart

Pardes Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Asset

Pardes Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Asset	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Pardes Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Pardes Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pardes Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pardes Biosciences's Debt-to-Asset falls into.

Pardes Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pardes Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	200.621
	=	0.00

Pardes Biosciences's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	157.31
	=	0.00

Pardes Biosciences (NAS:PRDS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Pardes Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pardes Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pardes Biosciences (Pardes Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pardes Biosciences Inc (NAS:PRDS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2173 Salk Avenue, Suite 250, PMB No. 052, Carlsbad, CA, USA, 92008

Website

https://www.pardesbio.com

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.

Executives

Fs Development Holdings Ii, Llc	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Opportunity Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Sean P. Brusky	officer: Chief Commercial Officer	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Thomas G Wiggans	director, officer: Chief Executive Officer
Foresite Capital Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Pottage John C Jr	director	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Alsup Laurie Smaldone	director	190 WOOSAMONSA RD, PENNINGTON NJ 08534
Heidi Henson	officer: Chief Financial Officer	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Brian Philippe Tinmouth	officer: Chief Business & Strategy Ofcr	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Brian Kearney	officer: Chief Development Officer	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Lee D Arnold	officer: Chief Scientific Officer	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Uri A Lopatin	director, officer: President and CEO	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013